
SỬ#DỤNG#CHỐNG#ĐÔNG#Ở#NGƯỜI##
BỆNH$VAN$TIM$1,2,3$$$
1. Bệnh#VHL#do#thấp,#nhịp#xoang,#NT#<55mm:#không#dùng#thuốc#chống#ngưng#
tập#TC#hay#VKA#(IITC).#
2. Bệnh#VHL#do#thấp,#nhịp#xoang,#NT#>=55mm:#dùng#VKA#với#INR=2T3#(IITC).#
3. Bệnh#VHL#do#thấp#có#HK#NT:#dùng#VKA#với#INR=2T3#(ITA)#
4. Bệnh#VHL#do#thấp#có#AF#hoặc#tắc#mạch#hệ#thống:#dùng#VKA#với#INR=2T3#(ITA)#
5. BN#c/b#nong#van#2#lá#bằng#bóng#có#HKNT#trên#TEE:#dùng#VKA#với#INR=2,5T3,5#
cho#đến#khi#KT#lại#bằng#TEE#thấy#hết#HKNT.#
#
1. Richard# P.# Whitlock# et# al.# AnRthromboRc$ and$ ThrombolyRc$ Therapy$ for$ Valvular$ Disease.$ AnRthromboRc$ Therapy$ and$
PrevenRon$ of$ Thrombosis,$ 9th$ ed:$ ACCP$ EvidenceaBased$ Clinical$ PracRce$ Guidelines.# CHEST# 2012;# 141(2)# (Suppl):e576S–
e600S#.#
2. Helmut#Baumgartner#et#al.#2017$ESC/EACTS$Guidelines$for$the$management$of$valvular$heart$disease.$The$Task$Force$for$the$
Management$ of$ Valvular$ Heart$ Disease$ of$ the$ ESC/$ EACTS.# European# Heart# Journal# (2017)# 38,# 2739–2791.# doi:10.1093/
eurheartj/ehx391#
3. Rick#A.#Nishimura#et#al.#2017$AHA/ACC$focused$update$of$the$2014$AHA/ACC$guideline$for$the$management$of$paRents$with$
valvular$heart$disease.#JACC.#Vol.#70,#No.#2,#2017.#July#11,#2017:252T89.#h{p://dx.doi.org/#10.1016/#j.jacc.#2017.03.011###